Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: Clinical and in vitro studies

Robert T. Means, Nancy J. Olsen, Sanford B. Krantz, Emmanuel N. Dessypris, Stanley E. Graber, William J. Stone, Vicki L. O'Neil, Theodore Pincus

Research output: Contribution to journalArticlepeer-review

104 Scopus citations

Abstract

Two anemic patients with rheumatoid arthritis were treated with recombinant human erythropoietin (EPO) for 5 months. Both patients showed significant increases in hematocrit, red cell volumes, and marrow erythroid and megakaryocyte progenitor cells. No significant toxic effects from EPO were observed. These data indicate that EPO may be effective in overcoming the pathogenetic factors that limit erythropoiesis in rheumatoid arthritis.

Original languageEnglish (US)
Pages (from-to)638-642
Number of pages5
JournalArthritis & Rheumatism
Volume32
Issue number5
DOIs
StatePublished - May 1989

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: Clinical and in vitro studies'. Together they form a unique fingerprint.

Cite this